Julie Brush, Solutus founding partner. Once upon a time, there was a lawyer. She was a solid lawyer: Heads down, hard worker and always ready to solve the next legal issue with precision and ...

By Daniella Parra Acumen Pharmaceuticals said it will present new research on its Alzheimer’s treatment candidate at the International Conference on Alzheimer’s and Parkinson’s Diseases 2026 in ...

Acumen Pharmaceuticals is developing an Alzheimer’s disease drug that it believes offers advantages compared to other approaches—including the recently approved Biogen therapy. A small clinical trial ...

“Think of a simple process that you know well,” Box Senior Director of Mid-Market Sales Raven Miles often instructs her sales reps. She gives them a moment as they consider the minutia of their daily ...

Strategic thinking involves seeing the big picture of your business and the specific paths to its growth amid changing consumer trends and competition. Having business acumen means understanding all ...

Acumen Pharmaceuticals is showing it has the business acumen to bring forward its Alzheimer's disease drug candidate. Investors seem to have taken stock of this on the company's first day of trading.

NEWTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that ...

NEWTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

A few years ago, Acumen, the pioneering patient capital impact investment firm, developed a unique method for measuring impact called Lean Data. Now, it’s spinning off that approach into a separate ...

Enrollment complete for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease Anticipate topline results in late 2026 Topline results from the ...

Engineering teams face steep challenges when it comes to staying on schedule, and keeping to those schedules can have an impact on the entire organization. Acumen, an Israeli engineering operations ...